XCMR Showcases Innovative UV-C Technology at ARPA-H BREATHE Proposer Day 2024

XCMR Co-founder and Chairman Kenneth Kelley presented the company’s innovative UV-C technology at the ARPA-H BREATHE Proposer Day, highlighting its potential to revolutionize respiratory protection.

The presentation emphasized the urgent need for advanced solutions to combat the significant challenges posed by airborne diseases.

XCMR’s proprietary UV-C microreactor technology offers a compelling alternative to traditional PPE, addressing limitations in efficacy, performance, and comfort.

The Advanced Research Projects Agency for Health (ARPA-H) accelerates better health outcomes for everyone by supporting the development of high-impact solutions to society’s most challenging health problems. The ARPA-H BREATHE (Building Resilient Environments for Air and Total Health) initiative aims to revolutionize public health by advancing our ability to monitor and improve indoor air quality and forecast emerging health threats.

To create a scalable system capable of monitoring and managing indoor air, BREATHE will engage performers across a range of expertise, including molecular diagnostic testing and biosensor instrument developers, data analysts, risk assessment software developers, property management firms, and others. The program has three technical areas: creating indoor biosensors, developing respiratory risk assessment software, and installing systems in buildings to cost-effectively deliver healthier air when needed.

The ARPA-H BREATHE Proposer Day aims to accelerate the development of innovative technologies to combat respiratory diseases. It brings together researchers, innovators, and industry leaders to showcase their groundbreaking solutions and explore potential collaborations to address the pressing challenges in respiratory health.

XCMR’s presentation: Transformative Respiratory Protection

At the 2024 BREATHE Proposer Day, XCMR’s co-founder and chairman, Ken Kelley, presented a poster titled “Transformative Respiratory Protection: Next Generation PPE with NIP.” The presentation underscored the critical need for advancements in respiratory protection, particularly in light of the global impact of aerosol-transmitted diseases. XCMR’s UV-C technology offers a compelling solution to address the limitations of traditional PPE, which often relies on filtration and can be uncomfortable, cumbersome, and single-use.

XCMR’s unique value proposition:

Pathogen Inactivation: XCMR’s UV-C reactors effectively inactivate a broad spectrum of pathogens (>95%) during inhalation and exhalation, providing a proactive defense against airborne threats.
Enhanced User Experience: The technology offers reduced weight, sound, and improved breathability, reusability, and comfort compared to traditional PPE, promoting greater compliance and effectiveness.
Connectivity and Data-Driven Insights: Integration with XCMR’s EMITR™ platform enables real-time monitoring, data analysis, and AI-driven insights to enhance infection transmission resiliency.

Looking ahead

XCMR’s participation in the 2024 ARPA-H BREATHE Proposer Day underscored the company’s dedication to transforming respiratory protection through innovative UV-C technology. By addressing the limitations of traditional PPE and offering solutions that prioritize efficacy, performance, and comfort, XCMR is actively contributing to the fight against respiratory diseases and shaping the future of biodefense. By collaborating with other innovators and leveraging its expertise, XCMR could contribute significantly to the BREATHE program’s vision of creating healthier indoor environments.